25-count (25 Vial Carton Label)
Levetiracetam Injection
Product Images NDC 58657-860
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 58657-860). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Method Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Equation 3 (3aa78fb2 1c58 4793 Acf9 6bb61c7d6115 00)
Equation 2 (3aa78fb2 1c58 4793 Acf9 6bb61c7d6115 01)
This is a formula for calculating the creatinine clearance (CrCl) of a patient, which is a measure of how well the kidneys are functioning. The formula takes into account the patient's age, weight, and serum creatinine level. The result is expressed in ml/min.*
Equation 1 (3aa78fb2 1c58 4793 Acf9 6bb61c7d6115 02)
Single-dose-vial (5ml Single Dose Vial)
This text provides information about a pharmaceutical product - Levetiracetam Injection, USP, with a concentration of 500 mg/5 mL. It is for intravenous use only and must be diluted before administration. The medication comes in a 5 mL single-dose vial and should be stored at 25°C (77°F). The description also includes details about the ingredients in the medication, such as sodium acetate trihydrate and sodium chloride. The usual dosage and storage instructions are also mentioned. Additionally, it is indicated to see the package insert for complete dosage recommendations.*
10-count (Carton Label)
This text appears to be a list of different pharmaceutical products and dosage instructions. It mentions various types of injections such as Levetiracetam Injection, USP and Single-Dose Vials. The text highlights the need for dilution before administration and proper storage conditions for the medications.*
Structural Formula (Image 01)
Figure 1 (Image 02)
This is a statistical comparison involving different percentages of a placebo and two doses of Levetiracetam. The percentage changes in effectiveness are compared to placebo for different doses of Levetiracetam. The study involves 95 participants for the 1,000 mg/day dose and 97 participants for the 3,000 mg/day dose of Levetiracetam. The comparison is statistically significant.*
Figure 2 (Image 03)
This is a clinical trial data showing the percentages of different groups taking placebo, Levetiracetam 1,000 mg/day, and Levetiracetam 2,000 mg/day. The statistical significance is noted for the group taking Levetiracetam compared to the placebo group.*
Figure 3 (Image 04)
This text provides a comparison of percentages: 45%, 39.4%, 40%, 35% against 14.4%, 10%, and 0%. It also mentions a study with a placebo group of 104 individuals and a Levetiracetam group of 180 individuals taking 3,000 mg/day. The study indicates that the results for Levetiracetam were statistically significant compared to the placebo.*
Figure 4 (Image 05)
From the provided text, it appears to be referencing a clinical trial or study involving a comparison between a placebo group and a group treated with levetiracetam. The percentages mentioned could represent the effectiveness or outcomes for each group. The statement "*statistically significant versus placebo" suggests that there was a significant difference between the effects of levetiracetam and the placebo. The total number of participants in the study is indicated as N=101 for the levetiracetam group.*
Figure 5 (Image 06)
This is a statistical data comparison between a placebo group (N=51) and a levetiracetam group (N=38). The percentages provided indicate the differences in results between the two groups, with a note that the outcomes are statistically significant when compared to the placebo.*
Figure 6 (Image 07)
This text provides statistical information to evaluate the effect of Levetiracetam on a group of 79 individuals compared to a placebo on a group of 84 individuals. The results show a statistically significant difference favoring Levetiracetam over the placebo.*
Single-dose-carton-labe (Single Dose Carton Label)
This is a product label for Levetiracetam Injection, USP. Each vial contains 500 mg of levetiracetam, 8.2 mg of sodium acetate trihydrate, and 45 mg of sodium chloride, with glacial acetic acid for pH adjustment. The injection is for intravenous use only and must be diluted before administration. The recommend storage temperature is 25°C (77°F), with excursions permitted between 15-30°C (59-86°F). The manufacturer is Method Pharmaceutical, LLC located in Southlake, TX. Please refer to the packaging for complete dosage recommendations. Any unused portion should be discarded.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
